ArticleJournal of gastroenterology2026
DH-AUTAC induces ferroptosis in colorectal cancer by targeting DHODH for autophagic degradation through KCTD10-SQSTM1 signaling.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDihydroorotate dehydrogenase (DHODH) is a critical enzyme involved in pyrimidine biosynthesis anda key suppressor of ferroptosis. This enzyme is commonly overexpressed in colorectal cancer (CRC), and itsupregulation facilitates the malignant progression of CRC tumors. METHODS & MECHANISMS: This study explored the endogenous degradation mechanism of DHODH in CRC.Mechanistically, DHODH is eliminated through KCTD10-mediated selective autophagy. As a substrate-specifi cadaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, KCTD10 induces K63-linked ubiquitination of DHODH. Theautophagy receptor SQSTM1/p62 subsequently recognizes the ubiquitinated DHODH and mediates its lysosomal-dependent degradation. Based on this molecular regulatory axis, we constructed DH-AUTAC, a novel autophagy-targeting chimera designed to specifi cally recruit endogenous DHODH to the autophagy system for targeteddegradation.
resultsIn vitro cell experiments and in vivo animal model assays consistently verifi ed the functional effi cacy ofDH-AUTAC. DH-AUTAC treatment effi ciently degraded DHODH protein, triggered robust ferroptosis, and therebymarkedly suppressed the proliferation of CRC cells and the growth of subcutaneous tumors. Pharmacologicalintervention experiments further showed that inhibiting ferroptosis completely abrogated the antitumor eff ects ofDH-AUTAC, whereas combined treatment with the autophagy and ferroptosis activator ATA194 signifi cantlyaugmented its therapeutic effi cacy. Moreover, animal model observations confi rmed that DH-AUTAC possessed agood in vivo safety profi le with no obvious adverse eff ects.
conclusionThis study identifi es a previously unreported molecular regulatory axis governing DHODH degradationin CRC. It also establishes an innovative AUTAC-based targeted protein degradation strategy to selectively activateferroptosis. Collectively, these fi ndings highlight the promising translational potential of targeted ferroptosisinduction as a novel therapeutic approach for clinical CRC treatment.
Indexed as
Identifiers
42622824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.